Cholesterol Drug Has a Favorable Effect on the Chronic Kidney Disease
Lipitor which is basically given to treat cholesterol is found to improve their kidney function in patients with heart disease. // It is manufactured by Pfizer Inc. he said that those patients who took 80 mg of the drug showed the highest improvement in the kidney function. The drug is the world's top-selling prescription drug. The data of the study was presented at the Ameri...
Sub-Saharan Africans With HIV May Achieve Favorable Levels of ART Adherence
A review of previous studies suggests that
favorable levels of antiretroviral therapy adherence can be reached among HIV-infected patients in sub-Saharan Africa,// while adherence remains a concern in North America. Antiretroviral therapy (ART) has improved the health of many human immunodeficiency virus (HIV) positive individuals who otherwise would have died. However, treatment eff...
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...
Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Jun 28, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI) announced on Wednesday,June 27 at the Jefferies Healthcare Conference that its interimanalysis of the blinded data on the first fifty patients in theFast-Tracked Phase 3 clinical study of SinuNase(TM), at 8 weekspost-randomization, has demonstrated substantial improvement inresolution of one or both...
Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial
of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable
Cytogenetics at EHA Meeting
NEW HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- VionPharmaceuticals, Inc. announced that it presented clinical data ina poster session at the 12th Congress of the European HematologyAssociation (EHA) Meeting in Vienna, Austria on its lead anticanceragent Cloretazine(R) (VNP40101M) as a single agent in amulti-center international Phase II clinical trial in a subset ofelderly pat...
Antipsychotic Iloperidone Results Show Favorable Akathisia Profile
SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- According tostudy results presented today at the 2007 American PsychiatricAssociation annual meeting, iloperidone, an investigationalatypical antipsychotic, was shown to have a
favorable akathisiaprofile. Akathisia -- a debilitating sensation of restlessness thatmanifests as an inability to sit still -- is a frequent side effectof antipsy...
New Long-Term Data Analyses for Bifeprunox Show Favorable Effects
Versus Placebo in Stabilized Patients with Schizophrenia
Six-Month Data Show Bifeprunox Maintained StabilitySignificantly Longer than Placebo and had a
Favorable Weight andLipid Profile Comparable with Placebo MARIETTA, Ga. and COLLEGEVILLE, Pa., May 22, 2007 - SolvayPharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth(NYSE:WYE), and Lundbeck A/S presented clinical study results onbifeprunox, an investigational treatment for...
More>>